Clinical Trial Update: A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. [Phase 1, Phase 2]

View source ↗

Summary

Phase 1b/2 study of a dual-target CD19/BCMA CAR T cell therapy for relapsed or refractory light-chain (AL) amyloidosis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Light-chain Amyloidosis

Drugs mentioned

• CD19/BCMA dual-target CAR T cell therapy (CAR T cell therapy targeting CD19 and BCMA)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Relapsed AL Amyloidosis, Refractory AL Amyloidosis | Phase 1, Phase 2 | Status: RECRUITING